News Galecto, Inc.

Equities

GLTO

US36322Q1076

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
0.49 ^USD	-0.24%		-0.26%	-31.94%

10/06	Oppenheimer Adjusts Price Target on Galecto to $9 From $10, Maintains Outperform Rating	MT
01/05	Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Price Target on Galecto to $9 From $10, Maintains Outperform Rating	10/06	MT
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	02/05	AQ
Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	02/05	CI
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04	CI
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	09/03	CI
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	22/12	MT
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis	22/12	AQ
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	22/12	CI
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)	23/23/23	PU
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial	23/23/23	AQ
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial	23/23/23	CI
HC Wainwright Downgrades Galecto to Neutral From Buy	28/23/28	MT
Galecto Announces Plans to Explore Strategic Alternatives	27/23/27	CI
Galecto to Explore Strategic Options, to Reduce Workforce	27/23/27	MT
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023	27/23/27	CI
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount	27/23/27	CI
Galecto Announces Plans to Explore Strategic Alternatives	27/23/27	AQ
Galecto to Present at Investor Conferences in September	31/23/31	AQ
HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	21/23/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Galecto, Inc.

Equities

GLTO

US36322Q1076

Summary

Filters